Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	1. participant is not expected to survive more than 24 hours. 2. participant has an unresolved neisseria meningitides infection. 3. hypersensitivity to murine proteins or to one of the excipients of ravulizumab.	1. participant is not expected to survive more than 24 hours. 2. participant has an unresolved neisseria meningitides infection. 3. hypersensitivity to murine proteins or to one of the excipients of ravulizumab.
Nov. 16, 2021, 6:30 p.m.	usa	participant is not expected to survive more than 24 hours. participant has an unresolved neisseria meningitides infection. hypersensitivity to murine proteins or to one of the excipients of ravulizumab.	participant is not expected to survive more than 24 hours. participant has an unresolved neisseria meningitides infection. hypersensitivity to murine proteins or to one of the excipients of ravulizumab.
Oct. 26, 2020, 11:31 p.m.	usa	1. participant is not expected to survive more than 24 hours. 2. participant has an unresolved neisseria meningitides infection. 3. hypersensitivity to murine proteins or to one of the excipients of ravulizumab.	1. participant is not expected to survive more than 24 hours. 2. participant has an unresolved neisseria meningitides infection. 3. hypersensitivity to murine proteins or to one of the excipients of ravulizumab.